Despite Drug Trial Miss, Here's Why Biogen Should Trade Higher
December 09, 2016 at 13:18 PM EST
BMO Capital Markets said Biogen Inc (NASDAQ: BIIB) shares should trade higher, despite a recent drug trial miss, on CTAD data (Clinical ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.